{"id":"W4414761454","doi":"10.1200/jco-25-01957","title":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Phases of clinical research; Clinical trial; Adverse effect; Primary (astronomy); Clinical endpoint; Safety profile","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001398254,0.000723,0.001364423,0.0001706024,0.0002212083,0.0007740853,0.0004360398,0.0005206674,0.001916915],"category_scores_gemma":[0.0007019961,0.0002133549,0.001024215,0.00019748,0.0004023176,0.0003978628,0.0002383846,0.001411332,0.0003110888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005341382,"about_ca_system_score_gemma":0.0005759922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004502168,"about_ca_topic_score_gemma":0.001930444,"domain_scores_codex":[0.9996777,0.0001991901,0.00001279938,0.00004237812,0.00002447905,0.00004356992],"domain_scores_gemma":[0.9995338,0.0001081391,0.000109344,0.00003194296,0.000015905,0.0002008784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8633206,0.008954002,0.007079342,0.0009591639,0.001997486,0.0001198319,0.0001684754,0.002278914,0.01193491,0.0003144408,0.003128244,0.09974453],"study_design_scores_gemma":[0.7161446,0.2436491,0.02690441,0.0001462494,0.002088577,0.0003573081,0.0000928561,0.003373081,0.002793558,0.000581528,0.003831643,0.0000370314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928073,0.004562648,0.0002046372,0.00030017,0.00009705637,0.0003824738,0.0004078085,0.00004360953,0.001194261],"genre_scores_gemma":[0.9948739,0.002041616,0.0004179465,0.0004361672,0.0001418865,0.0004653635,0.0006327878,0.00001261616,0.0009776682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001916915,"threshold_uncertainty_score":0.007394731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05260119380452237,"score_gpt":0.419853000832879,"score_spread":0.3672518070283566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}